Left ventricular dysfunction in an idiopathic pulmonary fibrosis patient on nintedanib

Abstract

Nintedanib, a tyrosine kinase inhibitor, is approved for the treatment of idiopathic pulmonary fibrosis. We report a case of left ventricular dysfunction in a patient with idiopathic pulmonary fibrosis treated with nintedanib, which recovered after cessation of nintedanib. Nintedanib may induce left ventricular dysfunction, and early recognition is important since this condition is potentially reversible.

Keywords

• Idiopathic pulmonary fibrosis
• left ventricular dysfunction
• nintedanib